References
- Michielin O, Van Akkooi A, Ascierto P, Dummer R, Keilholz U, ESMO Guidelines Committee. Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2019. doi: 10.1093/annonc/mdz411
- Cancer in Slovenia 2016. Ljubljana: Institute of Oncology Ljubljana, Epidemiology and Cancer Registry, Cancer Registry of Republic of Slovenia; 2019.
- National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines): cutaneus melanoma. Version 2.2019. [cited 2019 Sep 18]. Available at:
https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf - Robert C, Ribas A, Schachter J, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol 2019; 20: 1239-51. doi: 10.1016/S1470-2045(19)30388-2
- Long GV, Grob JJ, Nathan P, Ribas A, Robert C, Schadendorf D, et al. Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. Lancet Oncol 2016; 36: 667-73. doi: 10.1016/S1470-2045(16)30578-2.
- Weide B, Martens A, Hassel JC, Berking C, Postow MA, Bisschop K, et al. Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab. Clin Cancer Res 2016: 22; 5487-96. doi: 10.1158/1078-0432.CCR-16-0127
- Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ , Kefford R, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol 2019; 30: 582-8. doi: 10.1093/annonc/mdz011
- Schadendorf D, Livingstone E, Zimmer L. Treatment in metastatic melanoma - time to re-think. Ann Oncol 2019; 30: 501-3. doi: 10.1093/annonc/mdz050.
- Amid MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The eight edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin 2017; 67: 93-9. doi: 10.3322/caac.21388.
- Gershenwald JE, Scolyer RA, Hess KR, Sondak Vk, Long GV, Ross MI, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2017; 67: 472-92. doi: 10.3322/caac.21409
- Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47. doi: 10.1016/j.ejca.2008.10.026
- National Cancer Institute (NCI). NCI Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0. [cited 2019 Oct 17]. Available at:
https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf - Glitza Oliva IC, Schvartsman G, Tawbi H. Advances in the systemic treatment of melanoma brain metastasis. Ann Oncol 2018; 29: 1509-20. doi: 10.1093/annonc/mdy185
- Arbour KC, Mezquita L, Long N, Rizvi H, Auclin E, Ni A, et al. Impact of baseline steroids on efficacy of pembrolizumab or programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer. J Clin Oncol 2018; 36: 2872-8. doi: 10.1200/JCO.2018.79.0006
- Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Eng J Med 2015; 372: 2521-32. doi: 10.1056/NEJMoa1503093
- Algazi AP, Tsai KK, Shoushtari AN, Munhoz RR, Eroglu Z, Piulats JM, et al. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. Cancer 2016; 122: 3344-53. doi: 10.1002/cncr.30258
- Hamid O, Robert C, Ribas A, Stephen Hodi F, Walpole E, Daus A, et al. Anitumor activity of pembrolizumb in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006. Br J Cancer 2018; 119: 670-4. doi: 10.1038/s41416-018-0207-6
- Vrankar M, Unk M. Immune RECIST criteria and symptomatic pseudoprogression in non-small cell lung cancer patients treated with immunotherapy. Radiol Oncol 2018 52: 365-9. doi: 10.2478/raon-2018-0037
- Hodi FS, Hwu WJ, Kefford R, Weber JS, Daud A, Hamid O, et al. Evaluation of immune-related response criteria and RECIST v1.1. in patients with advanced melanoma treated with pembrolizumab. J Clin Oncol 2016; 34: 1510-7. doi: 10.1200/JCO.2015.64.0391
- Urugel S, Rohmal J, Ascierto PA, Flaherty KT, Grob JJ, Hauschild A, et al. Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017. Eur J Cancer 2017; 83: 247-57. doi: 10.1016/j. ejca.2017.06.028
- Archibald W, Victor AI, Strawderman MS, Maggiore RJ. Immune checkpoint inhibitors in older adults with melanoma or cutaneous malignancies: The Wilmot Cancer Institute experience. J Geriatr Oncol 2019; 11. doi: 10.1016/j.jgo.2019.07.005
- Champiat S, Lambotte O, Barreau E, Belkhir R, Berdelou A, Carbonnel F, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol 2016; 27: 559-74. doi: 10.1093/annonc/mdv623
- Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017; 28(Suppl 4): iv119-42. doi: 10.1093/annonc/mdx225
- Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of immune-related adverse events in patients treated with immnune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2018; 36: 1714-1768. doi: 10.1200/JCO.2017.77.6385
- Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 2019; 16: 563-80. doi: 10.1038/s41571-019-0218-0
- Danlos FX, Voisin AL, Dyevre V, Michot JM, Routier E, Taillade V, et al. Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. Eur J Cancer 2018; 91: 21-9. doi: 10.1016/j.ejca.2017.12.008
- Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blocade. N Eng J Med 2018; 378: 158-68. doi: 10.1056/NEJMra1703481.
- Leonardi GC, Gainor JF, Altan M, Kravets S, Dahlberg SE, Gedmintas L, et al. Safety of programmed death-1 pathway inhibitors among patients with non-small-cell lung cancer and pre-existing autoimmune disorders. J Clin Oncol 2018; 36: 1905-12. doi: 10.1200/JCO.2017.77.0305
- Renner A, Burotto M, Rojas C. Immune checkpoint inhibitor dosing: can we go lower without compromising clinical efficacy? J Global Oncol 2019; 5: 1-5. doi: 10.1200/JGO.19.00142
- Jansen YJL, Rozeman EA, Mason R, Goldinger SM, Geukes Foppen MH, Hoejberg L, et al. Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma. Ann Oncol 2019; 30: 1154-61. doi: 10.1093/annonc/mdz110
- Robert C, Ribas A, Hamid O, Daud A, Wolchok Jd, Joshua AM, et al. Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma. J Clin Oncol 2018; 36: 1668-74. doi: 10.1200/JCO.2017.75.6270
- Lorigan P, Eggermont AMM. Anti-PD1 treatment of advanced melanoma: development of criteria for a safe stop. Ann Oncol 2019; 30: 1038-40. doi: 10.1093/annonc/mdz182
- Daud AI, Wochok JD, Robert C, Hwu WJ, Weber JS, Ribas A, et al. Programmed death ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma. J Clin Oncol 2016; 34: 4102-9. doi: 10.1200/JCO.2016.67.2477
- Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, et al. iRECIST: guidelines for response criteria for use in trial testing immunotherapeutics. Lancet Oncol 2017. 18: e143-52. doi: 10.1016/S1470-2045(17)30074-8
- Robert C, Long GV, Brandy B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Eng J Med 2015; 372; 320-30. doi: 10.1056/NEJMoa1412082
- Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, et al. Five year survival with combined nivolumab and ipilimumab in advanced melanoma. N Eng J Med 2019; 381: 1535-46. doi: 10.1056/NEJMoa1910836
- Forsea AM, Del Marmol V, Stratigos A, Geller AC. Melanoma prognosis in Europe: far from equal. Br J Dermatol 2014; 171: 179-82. doi: 10.1111/bjd.12923